Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-715-8 | CAS number: 109-88-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Magnesium methanolate rapidly hydrolyzes in aqueous environments. Toxicity is mediated by its degradation products MeOH and Mg(OH)2 and assessed for these products.
MeOH
Methanol is readily absorbed after inhalation, ingestion and dermal contact and distributed rapidly throughout the body. The clearance from the body is mainly due to metabolism (up to 98%), with more than 90% of the administered dose exhaled as carbon dioxide. Renal and pulmonary excretion rates contribute to only about 2 – 3%. The metabolism and toxicokinetics of methanol varies by species and dose. In humans, the half-life time is approximately 2.5 – 3 hours at doses lower than 100 mg/kg bw. At higher doses, the half life can be 24 hours or more (IPCS/WHO, 1977; Kavet and Nauss, 1990).
The mammalian metabolism of methanol occurs mainly in the liver, where methanol is initially converted to formaldehyde, which is in turn converted to formate. Formate is converted to carbon dioxide and water. In humans and monkeys, the oxidation to formaldehyde is mediated by alcohol dehydrogenases and basically limited to the capacity of those enzymes. In rodents, the oxidation to formaldehyde predominantly employes the catalase-peroxidase pathway which is of less capacity than the ADH-pathway in humans but on the other hand produces oxygen radicals which may be involved into the developmental effects in rodents which - in contrast to humans - tolerate high methanol levels without signs of CNS or retinal toxicity. The last oxidation step, conversion of formate to carbon dioxide employes formyl-tetrahydrofolate synthetase a co-enzyme, is of comparably low capacity in primates which leads to a low clearance of formate, possibly also from sensitive target tissues (such as CNS and the retina) (DFG 1999; IPCS/WHO, 1997; Dorman et al., 1994; Medinsky et al., 1997, Medinsky and Dorman, 1995; Mc Martin et al., 1977).
In humans, when exposed to methanol via inhalation up to an air concentration 65 mg/m3, no increase of blood methanol is expected. Up to 260 mg/m3 (single or repeated exposure) the methanol blood level is likely to increase only 2- to 4- fold above the endogenous methanol concentration in humans, but still remains significantly below 10 mg/L (Lee et al., 1992; NTP, 2003). Up to air concentrations of 1600 mg/m3 the blood methanol levels increase to a similar extent in rats, monkeys, and humans. However, above this concentration rats show a steep exponential increase which apparently reflects the saturation of the catalase-dependent pathway. A smaller exponential increase was observed in monkeys, whereas in humans there appears to be a linear relationship between air concentrations and blood methanol levels.
Baseline levels of formate in blood are about 3 to 19 mg/L (0.07 – 0.4 mM) in humans. Toxic blood formate concentrations are reported to be 220 mg/L and higher (> 5 mM formate). Inhalation of about 1200 mg methanol/m3 for 2.5 hours contributed only insignificantly to the internal formate pool in monkeys (in the μM-range). This also hold true for folate-deficient conditions. After repeated inhalation of 2600 mg/m3 for 6 hours/day, 5 days/week, for 1 or 2 weeks, monkeys showed no discernible increase in formate concentrations in blood (estimated body burden 200 to 300 mg/kg bw/d). Formate accumulation, however, has been observed in primates upon bolus administration of more than 500 mg Methanol/kg bw (Horton et al., 1992; Medinsky and Dorman, 1995). The critical methanol dose that saturates the folate pathway in humans is estimated to be ≥ 200 mg/kg bw. Based on data produced in monkeys, metabolic saturation in humans is also less likely to happen upon inhalation where the dose is distributed over several hours (DFG 1999; IPCS/WHO, 1997; Burbacher et al., 1999).
There is a strong link between saturation (zero-order) kinetics and the onset of acute toxic effects. Exposure levels in humans above 5000 ppm (750 mg/kg bw in the course of 8 hrs) are prone to a zero order kinetic and a strong accumulation of methanol in the blood. Transient blindness has been reported for exposure levels between 1000 and 5000 ppm. (this saturation point could be reached after oral uptake at lower dose levels.) 10.000 ppm are still tolerated in rodents but would be highly detrimental in humans.
Mg(OH)2
In general solids need to be dissolved before they can be absorbed, and the water solubility of magnesium hydroxide is relatively low (~2 mg/L). Most studies suggest that magnesium is absorbed predominantly in the distal intestine. Magnesium absorption occurs primarily by intercellular diffusional and solvent drag mechanisms, as expected based on its low molecular weight. The bioavailability of orally administered magnesium salts is estimated to be 30-50%. For risk assessment purposes oral absorption of magnesium hydroxide is set at 50%. The results of the toxicity studies do not provide reasons to deviate from this proposed oral absorption factor.
Once absorbed, distribution of magnesium hydroxide throughout the body is expected based on its relatively low molecular weight. About 40% of plasma magnesium is protein bound. Signs of magnesium toxicity appear at serum magnesium concentrations of 1.5 mmol/L. Magnesium ions cross the placenta and are rapidly taken up by fetal tissues. Magnesium may be incorporated into the hair and nails. Magnesium hydroxide has characteristics favourable for fast urinary excretion: low molecular weight (below 300), reasonable water solubility, and ionization of the molecule at the pH of urine. Urinary magnesium excretion is very rapid in humans with normal renal function, the magnesium clearance increasing as a roughly linear function of the serum magnesium concentration.
Magnesium hydroxide particles have the potential to be inhaled by humans. Particles with aerodynamic diameters below 50 μm may reach the thoracic region and those below 15 μm the alveolar region of the respiratory tract. Low water solubility and small particle size will enhance penetration to the lower respiratory tract. Small ions will diffuse through aqueous channels and pores. For risk assessment purposes the inhalation absorption of magnesium hydroxide is set at 100%.
The skin sensitisation study is being treated as a false positive. The low molecular weight of magnesium hydroxide (less than 100) favours dermal uptake, but based on its water solubility(~2 mg/L), absorption is anticipated to be low to moderate. Although a partition coefficient cannot be determined for magnesium hydroxide, it is considered to be <-1. This suggests that magnesium hydroxide is not sufficiently lipophilic to cross the stratum corneum and dermal absorption is likely to be low. Therefore, dermal absorption is not considered to exceed 50%.
Key value for chemical safety assessment
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.